Original Article
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
N Engl J Med 1999; 340:757-763March 11, 1999
- Abstract
Background
Drug-induced psychosis is a difficult problem to manage in patients with Parkinson's disease. Multiple open-label studies have reported that treatment with clozapine at low doses ameliorates psychosis without worsening parkinsonism.
Methods
We conducted a randomized, double-blind, placebo-controlled trial of low doses of clozapine (6.25 to 50 mg per day) in 60 patients at six sites over a period of 14 months. The patients (mean age, 72 years) had idiopathic Parkinson's disease and drug-induced psychosis of at least four weeks' duration. All the patients continued to receive fixed doses of antiparkinsonian drugs during the four weeks of the trial. Blood counts were monitored weekly in all the patients.
Results
The mean dose of clozapine was 24.7 mg per day. The patients in the clozapine group had significantly more improvement than those in the placebo group in all three of the measures used to determine the severity of psychosis. The mean (±SE) scores on the Clinical Global Impression Scale improved by 1.6±0.3 points for the patients receiving clozapine, as compared with 0.5±0.2 point for those receiving placebo (P<0.001). The score on the Brief Psychiatric Rating Scale improved by 9.3±1.5 points for the patients receiving clozapine, as compared with 2.6±1.3 points for those receiving placebo (P=0.002). The score on the Scale for the Assessment of Positive Symptoms improved by 11.8±2.0 points for the patients receiving clozapine, as compared with 3.8±1.9 points for those receiving placebo (P=0.01). Seven patients treated with clozapine had an improvement of at least three points on the seven-point Clinical Global Impression Scale, as compared with only one patient given placebo. Clozapine treatment improved tremor and had no deleterious effect on the severity of parkinsonism. In one patient, clozapine was discontinued because of leukopenia.
Conclusions
Clozapine, at daily doses of 50 mg or less, is safe and significantly improves drug-induced psychosis without worsening parkinsonism.
Media in This Article
Table 1
Base-Line Characteristics of the Patients According to Treatment Actually Received.Table 2
Psychoactive Drugs Taken during the Study, According to Treatment Group.Article Activity
- Article
Drug-induced psychosis in patients with Parkinson's disease is a difficult problem to manage.1,2 It is the single most important factor leading to the placement of such patients in nursing homes,3 and it causes more stress for care givers than does motor dysfunction.4 Estimates of the frequency of drug-induced psychosis are as high as 22 percent.2,5,6 Until recently, the treatment of drug-induced psychosis was limited to reducing the dose of antiparkinsonian medication, adding a neuroleptic drug, discontinuing drug therapy for a period,7-10 or using electroconvulsive therapy.11
The introduction of the “atypical” antipsychotic drugs — those with few or no extrapyramidal side effects12 — raised the possibility of treating drug-induced psychosis without reducing motor function in patients with Parkinson's disease. Clozapine is virtually free of extrapyramidal side effects.13 It causes potentially fatal agranulocytosis14 in 1 to 2 percent of those exposed, however, and the Food and Drug Administration has mandated weekly blood-count monitoring of patients taking this drug. Such monitoring has made fatal agranulocytosis a rare event.15 Since the first report of the successful use of clozapine in treating drug-induced psychosis in patients with Parkinson's disease,16 there have been confirmatory reports of its effectiveness, but all such reports were from open-label studies.17-39 These studies, involving a total of more than 400 patients, reported significant benefit in approximately 85 percent of patients using 1/10 or less of the usual dosage of clozapine prescribed for schizophrenia. Open-label studies of the newer atypical antipsychotic drugs risperidone and olanzapine in patients with Parkinson's disease have yielded conflicting results,40-45 with clear worsening of motor signs in some patients.40,41,43,44 We report the results of a multicenter, randomized, placebo-controlled, double-blind study of clozapine for the treatment of drug-induced psychosis in patients with Parkinson's disease.
Methods
Patients
Patients were candidates for the study if they had idiopathic Parkinson's disease and psychosis induced by antiparkinsonian drugs. Parkinson's disease was diagnosed when at least three of the four cardinal features were present (tremor at rest, rigidity, hypokinesia, and problems with posture and balance typical of Parkinson's disease) and there were no alternative explanations for the findings. Psychosis was defined as a major psychiatric illness in which reality testing was impaired, typically by the presence of hallucinations or delusions, leading to substantial communication and social problems.46 Neither age nor the severity of motor dysfunction was a factor in the selection of patients. Special attempts were made to recruit women and members of minority groups. The protocol was approved by the institutional review board at each participating site.
Before entering the study, each patient was treated as deemed most appropriate by the enrolling investigator but without an antipsychotic drug. Patients were excluded if they had taken clozapine or a neuroleptic drug within three months before the start of the study. The doses of antiparkinsonian medications were generally reduced to the lowest level that was considered tolerable for motor function. To prevent the enrollment of patients whose improvement was the result of an adjustment of their antiparkinsonian medication, all the patients had to have been taking a fixed dose of medication for at least seven days before enrollment. The criteria for study entry were psychosis severe enough to have warranted treatment with a standard neuroleptic drug if the patient had not had Parkinson's disease and a score of 3 (indicating mild psychosis) or higher on the Clinical Global Impression Scale47 for the severity of psychosis.
To be included in the study, each patient had to have a documented history of psychosis of at least four weeks' duration before enrollment and had to have a reliable care giver who could accurately report the patient's daily level of function, accompany the patient to each visit, and administer the study drug.
Criteria for exclusion were a history of leukopenia; the presence of any systemic factor that might contribute to a behavioral disorder; therapy with any dopamine-blocking drug within the three months before the study began; therapy with neuroleptic drugs administered in depot form within the year before the study; a change in antidepressant or anxiolytic drugs within the month before the study; previous therapy with clozapine for the treatment of psychosis; the presence of symptomatic orthostatic hypotension, uncontrolled seizures, uncontrolled angina, the acquired immunodeficiency syndrome or another illness that would make the use of clozapine potentially hazardous, or narrow-angle glaucoma; myocardial infarction during the three months before the study; treatment with chemotherapeutic drugs that lower white-cell counts; an inability to tolerate a fixed dose of antiparkinsonian drugs for one month; an inability to tolerate the current level of psychosis for one month; or the presence of dementia severe enough to preclude assessment on the psychiatric-test battery. Women of childbearing potential who were not using reliable forms of contraception were also excluded.
Design of the Study
The study was designed to determine whether clozapine, administered at low doses, is an effective treatment for drug-induced psychosis in patients with Parkinson's disease and to determine its effect on motor function in such patients. The primary outcome measures were the scores on the Clinical Global Impression Scale47 for psychosis and the Unified Parkinson's Disease Rating Scale for parkinsonism.48
If the screening laboratory tests revealed no clinically significant abnormality, the patient or his or her legal guardian was asked to give written informed consent. The patient was then enrolled in the Clozaril Patient Monitoring System administered by Sandoz Pharmaceuticals (now Novartis Pharmaceuticals, Hanover, N.J.) and enrolled in the study. The random assignment of the patients to the clozapine group or the placebo group was stratified according to the site and the age of the patient (under 70 years vs. 70 or older).
The double-blind evaluation lasted four weeks. At base line, a physical examination was conducted and the Mini–Mental State Examination49 was administered. Three measures of psychosis were used: the Clinical Global Impression Scale,47 which rates the severity of psychotic symptoms on a scale from 0 (no symptoms) to 7 (the most severe symptoms); the Scale for the Assessment of Positive Symptoms, in which the score for the severity of symptoms ranges from 0 (no symptoms) to 17650; and the Brief Psychiatric Rating Scale, in which scores can range from 18 to 126, with higher scores indicating more severe psychosis.51 A modified version of the Brief Psychiatric Rating Scale was also used in which the four items measuring tension, mannerisms, posturing, and motor retardation that we considered unreliable because of confounding with motor signs of Parkinson's disease were omitted.
All the patients were evaluated on the psychiatric scales by the site investigator (a neurologist or a psychiatrist). All the investigators were trained in the administration of the tests to patients with Parkinson's disease at a teaching session in which videotaped interviews were used, but no formal study of interrater reliability was performed. The severity of parkinsonism was assessed with the use of sections II and III of the Unified Parkinson's Disease Rating Scale (possible range of scores, 0 to 160),48 including the Step–Seconds Test, the Hoehn–Yahr staging system (stage I indicates newly diagnosed disease, and stages IV and V advanced disease),52 and the Schwab and England Activities of Daily Living scale (range of scores, 0 to 100, with lower scores indicating more severe dysfunction).53 The scores for tremor on the Unified Parkinson's Disease Rating Scale were analyzed in isolation because of reports that clozapine decreases tremor in Parkinson's disease.54-58 Adverse events and changes in sleep patterns were evaluated in detailed questionnaires.
Clozapine (Clozaril) was obtained in bulk from Sandoz Pharmaceuticals. It was ground into powder form and repackaged in 6.25-mg capsules along with matching placebo at the University of Rhode Island School of Pharmacy. At the time of study entry, the patients received a 10-day supply of the assigned medication and started taking one capsule each night. On day 3 or 4, the study coordinator or investigator spoke with the patients' care givers to determine, on the basis of an unstructured conversation carried out over the telephone, the response to treatment. The dose could then be increased or decreased. If there were adverse events before the scheduled phone call, the care givers were asked to contact the study coordinator or investigator. The patients were evaluated weekly in the office, where vital signs (pulse, blood pressure, and temperature), weight, adverse events, and compliance (measured by pill counts) were assessed. Telephone calls to the care givers were made mid-week. The investigators assessed the level of psychosis weekly.
Possible daily doses were as follows: 6.25, 12.5, 18.75, 25, 37.5, and 50 mg. All daily doses started at 6.25 mg and could be raised one level depending on the patient's clinical response; if the patient's daily dose had been increased from the initial 6.25-mg level, it could also be lowered one level. The dose could be changed once between weekly office visits or at the visit. A dose could be increased even if the patient had not been able to tolerate that dose on a previous occasion. The dosage reached at the beginning of the final week was the maximal dose; it could not be increased further but could be decreased, if necessary, because of side effects. Thus, at the final assessment, when all base-line measures were repeated, the patient had been receiving a stable or declining dose of study medicine for at least seven days.
During the study, all the patients had a complete blood count performed weekly. The results were reported to a monitor who was not aware of the patients' treatment assignments. Monitoring guidelines were the same as those for all patients in the Clozaril Patient Monitoring System. Since a request for an additional complete blood count if the white-cell count declined could reveal the treatment assignment to the participants, additional blood tests were also randomly performed. Thus, some patients had additional blood drawn even if the standard weekly complete blood count was normal. The results were available only to the monitor, who remained unaware of the treatment assignments. The study participants were not told whether the additional blood test was triggered by a decline in the white-cell count or was randomly ordered. At the end of the fourth week, all base-line tests were repeated.
Safety
A safety monitoring committee, composed of two physicians and a statistician who did not otherwise participate in the study, met quarterly. This committee reviewed all laboratory data and reports of adverse events; its members had full access to treatment assignments.
Statistical Analysis
Data were sent to the Clinical Trials Coordination Center (Rochester, N.Y.). Forms were reviewed for completeness and accuracy before the data were entered into the data base. The protocol required a sample of 60 subjects in order to have the power to demonstrate that clozapine did not worsen motor function in patients with Parkinson's disease. Unpublished data on drug-induced psychosis in patients with Parkinson's disease that were obtained with use of the Brief Psychiatric Rating Scale indicated that fewer patients would be required in order to demonstrate that clozapine improved drug-induced psychosis. Assuming a standard deviation of six units for the change from base line in the scores on the Unified Parkinson's Disease Rating Scale (items II and III) and a dropout rate of 10 percent, we estimated that a sample of 30 patients per treatment group would give the study a 90 percent power to detect a worsening of five points on the Unified Parkinson's Disease Rating Scale in the group assigned to clozapine (P=0.05 by a two-sided test),59 a decline thought to be clinically significant.
The base-line characteristics of the patients in the two groups were compared by chi-square tests or t-tests, as appropriate. The effect of treatment on each outcome measure was assessed by analysis of covariance, with adjustments made for the base-line value and the investigator. Consistency with respect to possible investigator bias was examined by the inclusion of terms for investigator–treatment interactions.
The intention-to-treat analysis called for in the protocol was modified to account for one patient who was randomly assigned to receive placebo but actually received clozapine. When this error was discovered midway through the trial, we opted to keep giving the patient the active drug. Very similar results with respect to efficacy were obtained regardless of whether this patient was excluded from or included in the group to which she had been randomly assigned. The analyses reported here are based on the treatment the patients received, not on the intention-to-treat analysis, and include data only for those who completed evaluations at base line and four weeks.
Results
Base-Line Characteristics
Sixty patients were enrolled between April 1995 and October 1996, with the numbers recruited varying from 9 to 12 patients per site. All had had hallucinations or delusions. There were some significant imbalances at base line between the groups in the intention-to-treat analysis (the patients receiving clozapine had slightly less severe psychosis than those receiving placebo), but not between the groups in the analysis based on the treatment the patients actually received (Table 1Table 1
Base-Line Characteristics of the Patients According to Treatment Actually Received.). Fifty-four patients completed the trial.The mean score at base line was 3.0 (indicating mild psychosis) or higher for the following individual items on the Brief Psychiatric Rating Scale only: anxiety, suspiciousness, and hallucinations. There were no significant differences in the use of antiparkinsonian or psychotropic drugs between the two groups (Table 2Table 2
Psychoactive Drugs Taken during the Study, According to Treatment Group.). All 60 patients were taking levodopa.Safety
Three patients receiving placebo and three receiving clozapine withdrew from the study. The psychiatric condition of two of the three patients receiving placebo worsened. One patient required psychiatric hospitalization, and the other discarded her medications, declaring herself “cured.” The third patient was hospitalized for pneumonia. Of the three patients in the clozapine group who withdrew from the study, one discontinued the drug because of leukopenia (white-cell count, 2900 per cubic millimeter), one because of myocardial infarction, and one because of sedation.
There were no significant changes in the mean neutrophil or white-cell counts in either group. There were no significant differences between groups in changes in orthostatic blood pressure, but there was a small but statistically significant increase from base line, of 3.9 beats per minute, in the mean resting heart rate of the patients receiving clozapine as compared with no increase in that of the patients receiving placebo (P=0.046). Weight increased by 0.7 kg (1.6 lb) in the patients receiving clozapine and 0.1 kg (0.27 lb) in those receiving placebo (P=0.005). There were no significant differences between the groups in the severity of drooling, memory impairment, constipation, orthostatic lightheadedness, urinary hesitancy, confusion, headaches, fatigue, or daytime sedation.
Analyses were repeated with the use of the intention-to-treat method, the last-observation-carried-forward method, or both methods; the results of all analyses were similar.
Efficacy
The mean daily dose of clozapine prescribed at the end of the study was 24.7 mg (range, 6.25 to 50). The mean daily dose of placebo was equivalent to 35.2 mg (range, 6.25 to 50).
Improvements were seen in all measures of psychosis in the clozapine group, including the Clinical Global Impression Scale, the Brief Psychiatric Rating Scale (original and modified versions), and the Scale for the Assessment of Positive Symptoms (Table 3Table 3
Changes in Scores for Primary Outcome Measures from Base Line to Follow-up.). In 13 patients in the clozapine group but in only 3 patients in the placebo group the severity of psychosis decreased to a level that, if present at base line, would have made them ineligible for the study. Table 4Table 4
Changes in Psychosis Scores from Base Line to Follow-up, as Measured by the Clinical Global Impression Scale. shows the distribution of changes in the scores on the Clinical Global Impression Scale. Hallucinations (almost entirely visual) improved by 1.9 points for the patients receiving clozapine and 0.7 point for those receiving placebo (P=0.002) on the Brief Psychiatric Rating Scale. There were no significant differences between the groups with respect to any of the five items on our sleep questionnaire.There was no worsening of motor symptoms in either group according to the measures of parkinsonism (Table 3). There was a statistically significant beneficial effect of clozapine on tremor, and there were no significant differences between the two groups with respect to the other measures of parkinsonism.
There were no statistically significant investigator–treatment interactions in any of the outcome measures, indicating consistency of results among investigators. Compliance, as measured by pill counts, was 96 percent in the placebo group and 98 percent in the clozapine group.
Discussion
In this double-blind study, clozapine ameliorated psychosis despite the fact that the patients continued taking antiparkinsonian drugs. Moreover, clozapine did not worsen motor function and actually decreased tremor.
Several aspects of our study design require explanation. We excluded patients whose psychosis had lasted for less than four weeks so as to avoid confounding between improvement due to clozapine and that due to a delayed response to a reduction in the dose of antiparkinsonian medication. Because there are no validated instruments for measuring psychosis in Parkinson's disease, we chose four separate measures of psychotic symptoms. The Clinical Global Impression Scale was the primary tool we used to measure the severity of psychosis. The Brief Psychiatric Rating Scale rates both positive (e.g., presence of hallucinations) and negative (e.g., absence of emotion) symptoms and is valid for assessing the severity of schizophrenia. We also used the Scale for the Assessment of Positive Symptoms, on the basis of numerous reports of drug-induced psychosis consisting of positive symptoms.60-64 We used these measures in combination to buttress the reliability of our results.
The patients in this study were fairly typical of those encountered in clinical practice, although we excluded those with the most severe psychosis because of our concern that four weeks of placebo therapy might jeopardize the patients' safety. We defined improvement of psychosis according to three separate clinical measures, and our results demonstrated both clinically and statistically significant improvement. These results held true in the analysis of the patients according to actual treatment as well as in the intention-to-treat analysis. The improvements were greater than those reported in most trials of antipsychotic drugs in schizophrenia.65,66 The finding that parkinsonism did not worsen in our study confirms the results of open-label studies. The improvement in tremor is commensurate with that in previous studies.54-58 Our results contrast markedly with those of the one previous placebo-controlled trial, which had only six subjects.67 The most obvious explanation for the difference in outcomes is the fact that higher doses were used in that study.
The reduction in the number of white cells in the patients receiving clozapine, necessitating discontinuation of the drug in one patient, is within the range expected on the basis of much larger samples. The complete blood count returned to normal once clozapine was discontinued. In more than 400 patients with Parkinson's disease who were treated with clozapine, there have been only 3 cases of leukopenia, a percentage somewhat smaller than that found in our study.37 Our results covered a period of four weeks, and the greatest risk of agranulocytosis extends through the first four months of treatment. Thus, clozapine can be safely given to elderly patients with Parkinson's disease for at least four weeks, with weekly monitoring of the white-cell count.
Although weekly visits could have revealed adverse effects that might have made the investigator aware of the treatment assignments, the nature and frequency of side effects were similar in the clozapine and placebo groups. Although clozapine has anticholinergic activity in the brain,68 we found that it did not impair memory or cognitive function as measured on the Mini–Mental State Examination. There were no anticholinergic effects, such as urinary retention, dry mouth, blurred vision, or constipation. Somnolence was as frequent in the placebo group as in the clozapine group, and there were no differences between the groups in any of the measures of sleep patterns — namely, the amount of time spent sleeping, the amount of time needed to fall asleep, and the duration of naps during the day.
Other adverse events associated with clozapine in our study were weight gain and an increase in the pulse rate. To our knowledge, weight gain in patients with drug-induced psychosis has not been noted before, although it has occurred in patients with Parkinson's disease who were treated with higher doses of clozapine for tremor.55 Weight gain is not necessarily a problem, since patients with Parkinson's disease commonly lose weight during the course of their illness. Tachycardia was asymptomatic in the patients in our study and was not of clinical importance. Whether this could be a problem for patients with unstable angina needs to be considered. Fever did not occur in our patients.
At the end of the double-blind trial, all the patients were offered treatment for three months with clozapine, provided free of charge. Fifty-three patients were enrolled in this open-label extension of the study. During the three-month extension, the white-cell count dropped to 3000 per cubic millimeter in one patient, who was then withdrawn from the study, after which the count returned to normal. Six patients died, three of whom had been living in nursing homes. Two of these three had advance directives limiting intervention; one died of a stroke and the other of bronchitis. The third nursing home resident died in her sleep of unknown causes. Two other patients died of pneumonia. The sixth patient died of cardiac arrest shortly after the three-month extension of the study ended. No deaths were associated with a low white-cell count. The site investigators did not believe clozapine was related to death in any of the patients. Other drugs were changed (the doses were either increased or decreased, or the drugs were discontinued, or new drugs were started) during this extension phase. We believe the deaths were due to complications of disease in patients who had generally requested that no aggressive interventions should be used to save their lives. Such a high death rate has not been reported before in studies of clozapine, but increased mortality and hallucinations have been reported in patients with Parkinson's disease in nursing homes.69
In summary, we found that clozapine at doses ranging from 6.25 to 50 mg per day, which are far lower than the doses of 300 to 900 mg required for the treatment of schizophrenia, reduced the severity of drug-induced psychosis in patients with Parkinson's disease. Although the most feared adverse effect is agranulocytosis, the incidence of which is reported to increase with age, it did not occur in our study. Leukopenia developed in one patient during the four weeks of clozapine therapy, but it resolved after clozapine was stopped. The fact that the three-month extension of the study had an open-label design makes it difficult to interpret the relation between clozapine and morbidity, since other drugs were changed during this period, but continued study of the morbidity and mortality associated with clozapine is appropriate.
Supported in part by a grant (FD-R-001416-02) from the Orphan Drug Division of the Food and Drug Administration and in part by the Parkinson Study Group.
We are indebted to Mary Eddy for assistance in the preparation of the manuscript; to R.B. Daroff, M.D., and H.Y. Meltzer, M.D., for editorial help; to Michael Dreiss, M.S., of the Food and Drug Administration for financial and administrative advice; to the white-cell count monitors at the study sites: D. Agle, M.D., E. Molho, M.D., P. O'Dowd, M.D., and A. Payne, R.N.; and to Sandoz Pharmaceuticals for providing clozapine.
Source Information
Address reprint requests to Dr. Joseph H. Friedman at the Memorial Hospital of Rhode Island, 111 Brewster St., Pawtucket, RI 02860, or at joseph_friedman@mhri.org. Dr. Friedman assumes responsibility for the overall content and integrity of the manuscript.
The members of the Parkinson Study Group who participated in the study are listed in the Appendix.
Appendix
The following persons participated in the study: Investigators — J. Friedman and M. Lannon, Memorial Hospital of Rhode Island, Pawtucket, and Brown University School of Medicine, Providence; C. Comella, Rush–Presbyterian–St. Luke's Medical Center and Rush School of Medicine, Chicago; S. Factor, Albany College of Medicine, Albany, N.Y.; R. Kurlan and I. Richard, University of Rochester, Rochester, N.Y.; M. Parsa, Case Western University School of Medicine, Cleveland; R. Pfeiffer, University of Tennessee Medical Center, Memphis; Study Coordinators — R. Davies, Memorial Hospital of Rhode Island, Pawtucket, and Brown University School of Medicine, Providence; K. Janko, Rush–Presbyterian–St. Luke's Medical Center, Chicago; D. Brown, Albany College of Medicine, Albany, N.Y.; I. Gardner and N. Pearson, University of Rochester, Rochester, N.Y.; K. Large, Case Western University School of Medicine, Cleveland; S. Rast, University of Tennessee Medical Center, Memphis; Steering Committee — D. Oakes, University of Rochester, Rochester, N.Y.; C. Goetz, Rush–Presbyterian–St. Luke's Medical Center, Chicago; G. Paulson, Ohio State University, Columbus; F. Marshall, K. Kieburtz, and A. Rudolph, University of Rochester, Rochester, N.Y.; Clinical Trials Coordination Center — K. Bourgeois, C. Casacelli, A. Freimuth, B. Guthrie, R. Pelusio, and A. Watts, University of Rochester, Rochester, N.Y.; Safety Monitoring Committee — P. Tariot and R. Raubertas, University of Rochester, Rochester, N.Y.; and T. Greenamyre, Emory University, Atlanta.
- References
References
1
Friedman JH . The management of levodopa psychoses. Clin Neuropharmacol 1991;14:283-295
CrossRef | Web of Science | Medline2
Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug-induced psychiatric states. In: Weiner WJ, Lang AE, eds. Behavioral neurology of movement disorders. Vol. 65 of Advances in neurology. New York: Raven Press, 1995:115-38.
3
Goetz CG ,Stebbins GT . Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-2229
Web of Science | Medline4
Carter JH ,Stewart BJ ,Archold PG . Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Mov Disord 1998;13:20-28
CrossRef | Web of Science | Medline5
Friedman A ,Sienkiewicz J . Psychotic complications of long-term levodopa treatment in Parkinson's disease. Acta Neurol Scand 1991;84:111-113
CrossRef | Web of Science | Medline6
Friedman JH. Management of psychosis in Parkinson's disease. In: Koller WC, Paulson G, eds. Therapy of Parkinson's disease. 2nd ed. rev. New York: Marcel Dekker, 1995:521-32.
7
Goetz CG ,Tanner CM ,Klawans HL . Drug holiday in the management of Parkinson's disease. Clin Neuropharmacol 1982;5:351-364
CrossRef | Web of Science | Medline8
Kofman OS . Are levodopa “drug holidays“ justified? Can J Neurol Sci 1984;11:Suppl:206-209
Web of Science | Medline9
Feldman RG ,Kaye JA ,Lannon MC . Parkinson's disease: follow-up after “drug holiday.“ J Clin Pharmacol 1986;26:662-667
Web of Science | Medline10
Kurlan R ,Tanner CM ,Goetz C , et al. Levodopa drug holiday versus drug dosage reduction in Parkinson's disease. Clin Neuropharmacol 1994;17:117-127
CrossRef | Web of Science11
Hurwitz TA ,Calne DB ,Waterman K . Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy. Can J Neurol Sci 1988;15:32-34
Web of Science | Medline12
Casey DE. What makes a neuroleptic atypical? In: Meltzer HY, ed. Novel antipsychotic drugs. New York: Raven Press, 1992:241-51.
13
Kane JM ,Honigfeld G ,Singer J ,Meltzer HY . Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
CrossRef | Web of Science | Medline14
Alvir JMJ ,Lieberman JA ,Safferman AZ ,Schwimmer JL ,Schaaf JA . Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329:162-167
Full Text | Web of Science | Medline15
Honigfeld G ,Arellano F ,Sethi J ,Bianchini A ,Schein J . Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998;59:Suppl 3:3-7
CrossRef | Web of Science | Medline16
Scholz E ,Dichgans J . Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci 1985;235:60-64
CrossRef | Medline17
Bear D ,Lawson W ,Burns S ,Tacke U . Clozapine in idiopathic Parkinsons. Biol Psychiatry 1989;25:Suppl:163a-163a abstract.
CrossRef18
Bernardi F ,Del Zompa M . Clozapine in idiopathic Parkinson's disease. Neurology 1990;40:1151-1152
Web of Science | Medline19
Chacko RC, Hurley RA, Harper RG, Jankovic J, Cardosa F. Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease.J Neuropsychiatry Clin Neurosci 1995;7:471-5.
20
Factor SA ,Brown D . Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 1992;7:125-131
CrossRef | Web of Science | Medline21
Factor SA ,Brown D ,Molho ES ,Podskalny GD . Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. Neurology 1994;44:544-546
Web of Science | Medline22
Friedman JH ,Max J ,Swift R . Idiopathic Parkinson's disease in a chronic schizophrenic patient: long-term treatment with clozapine and L-dopa. Clin Neuropharmacol 1987;10:470-475
CrossRef | Web of Science | Medline23
Friedman JH ,Lannon MC ,Caley C . Clozapine for movement disorder patients: a retrospective analysis of 38 patients. Ann Neurol 1992;32:277-277 abstract.
Web of Science24
Gonski PN . The use of clozapine in Parkinson's disease. Aust N Z J Med 1994;24:585-585
CrossRef | Medline25
Greene P ,Cote L ,Fahn S . Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv Neurol 1993;60:703-706
Web of Science | Medline26
Kahn N ,Freeman A ,Juncos JL ,Manning D ,Watts RL . Clozapine is beneficial for psychosis in Parkinson's disease. Neurology 1991;41:1699-1700
Web of Science | Medline27
Lanazasoro G ,Suerez JA ,Marti Masso JF . Clozapine in Parkinson's disease: three years experience. Mov Disord 1992;7:Suppl 1:100-100 abstract.
CrossRef28
Lew MF ,Waters CH . Clozapine treatment of parkinsonism with psychosis. J Am Geriatr Soc 1993;41:669-671
Web of Science | Medline29
Ostergaard K ,Dupont E . Clozapine treatment of drug-induced psychotic symptoms in late stages of Parkinson's disease. Acta Neurol Scand 1988;78:349-350
CrossRef | Web of Science | Medline30
Pfeiffer RF ,Kang J ,Graber B ,Hofman R ,Wilson J . Clozapine for psychosis in Parkinson's disease. Mov Disord 1990;5:239-242
CrossRef | Web of Science | Medline31
Pinter MM ,Helscher RJ . Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease. J Neural Transm Park Dis Dement Sect 1993;5:135-146
CrossRef | Medline32
Rabey JM ,Treves TA ,Neufeld MY ,Orlov E ,Korczyn AD . Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 1995;45:432-434
Web of Science | Medline33
Roberts HE ,Dean RC ,Stoudemire A . Clozapine treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1989;1:190-192
Medline34
Rosenthal SH ,Fenton ML ,Harnett DS . Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease. Gen Hosp Psychiatry 1992;14:285-286
CrossRef | Web of Science | Medline35
Ruggieri S ,De Pandis MF ,Bonamartini A ,Vacca L ,Stocchi F . Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease. Clin Neuropharmacol 1997;20:204-209
CrossRef | Web of Science | Medline36
Rui Silva M ,Magalhaes M ,Viseu M ,Bastos Lima A . Clozapine in the treatment of psychosis in parkinsonism. J Neurol 1995;242:Suppl 2:S138-S138 abstract.37
Trosch RM ,Friedman JH ,Lannon MC , et al. Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord 1998;13:377-382
CrossRef | Web of Science | Medline38
Wagner ML ,Defilippi JL ,Menza MA ,Sage JI . Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients. J Neuropsychiatry Clin Neurosci 1996;8:276-280
Web of Science | Medline39
Wolk SI ,Douglas CJ . Clozapine treatment of psychosis in Parkinson's disease: a report of five consecutive cases. J Clin Psychiatry 1992;53:373-376
Web of Science | Medline40
Ford B ,Lynch T ,Greene P . Risperidone in Parkinson's disease. Lancet 1994;344:681-681
CrossRef | Web of Science | Medline41
Friedman JH . Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1998;50:1195-1196
Web of Science | Medline42
Meco G ,Alessandri A ,Giustini P ,Bonifati V . Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Mov Disord 1997;12:610-612
CrossRef | Web of Science | Medline43
Jimenez-Jimenez FJ ,Talon-Barranco A ,Orti-Pareja M ,Zurdo M ,Porta J ,Molina JA . Olanzapine can worsen parkinsonism. Neurology 1998;50:1183-1184
Web of Science | Medline44
Rich SS ,Friedman JH ,Ott BR . Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995;56:556-559
Web of Science | Medline45
Wolters EC ,Jansen EN ,Tuynman-Qua HG ,Bergmans PLM . Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996;47:1085-1087
Web of Science | Medline46
Kaplan HI, Sadock BJ, Grebb JA. Kaplan and Sadock's synopsis of psychiatry. 7th ed. Baltimore: Williams & Wilkins, 1994.
47
Guy W, ed. ECDEU assessment manual for psychopharmacology. Rev. Rockville, Md.: Alcohol, Drug Abuse, and Mental Health Administration, 1976:217-22. (DHEW publication no. (ADM) 76-338.)
48
Lang AET, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, ed. Quantification of neurologic deficit. Boston: Butterworths, 1989:285-309.
49
Folstein MF, Folstein SE, McHugh PR. “Mini–Mental State”: a practical method for grading the cognitive state of patients for the clinician.J Psychiatric Res 1975;12:189-98.
50
Andreason NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa, 1984.
51
Overall JE ,Gorham DR . Introduction -- the Brief Psychiatric Rating Scale (BPRS): recent developments. Psychopharmacol Bull 1988;21:97-9952
Hoehn M ,Yahr M . Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442
Web of Science | Medline53
Schwab RS, England AC Jr. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson IM, eds. Third Symposium on Parkinson's Disease held at the Royal College of Surgeons of Edinburgh on 20, 21, and 22 May 1968. Edinburgh, Scotland: E. & S. Livingstone, 1969:152-7.
54
Pakkenberg H ,Pakkenberg B . Clozapine in the treatment of tremor. Acta Neurol Scand 1986;73:295-297
CrossRef | Web of Science | Medline55
Friedman JH ,Lannon MC . Clozapine-responsive tremor in Parkinson's disease. Mov Disord 1990;5:225-229
CrossRef | Web of Science | Medline56
Fischer PA ,Baas H ,Hefner R . Treatment of parkinsonian tremor with clozapine. J Neural Transm Park Dis Dement Sect 1990;2:233-238
CrossRef | Medline57
Jansen ENH . Clozapine in the treatment of tremor in Parkinson's disease. Acta Neurol Scand 1994;89:262-265
CrossRef | Web of Science | Medline58
Friedman JH ,Koller WC ,Lannon MC ,Busenbark K ,Swanson-Hyland E ,Smith D . Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Neurology 1997;48:1077-1081
Web of Science | Medline59
Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley, 1981:260-80.
60
Goetz CG ,Tanner CM ,Klawans HL . Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 1982;139:494-497
Web of Science | Medline61
Mindham RHS . Psychiatric symptoms in parkinsonism. J Neurol Neurosurg Psychiatry 1970;33:188-191
CrossRef | Web of Science | Medline62
Celesia GC ,Barr AN . Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 1970;23:193-200
Web of Science | Medline63
Goodwin FK . Psychiatric side effects of levodopa in man. JAMA 1971;218:1915-1920
CrossRef | Web of Science | Medline64
Jenkins RB ,Groh RH . Mental symptoms in parkinsonian patients treated with L-dopa. Lancet 1970;2:177-179
CrossRef | Web of Science | Medline65
Zimbroff DL ,Kane JM ,Tamminga CA , et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-791
Web of Science | Medline66
Beasley CM Jr ,Sanger T ,Satterlee W ,Tollefson G ,Tran P ,Hamilton S . Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996;124:159-167
CrossRef | Web of Science | Medline67
Wolters EC ,Hurwitz TA ,Mak E , et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990;40:832-834
Web of Science | Medline68
Bolden C ,Cusack B ,Richelson E . Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells. Eur J Pharmacol 1991;192:205-206
CrossRef | Web of Science | Medline69
Goetz CG ,Stebbins GT . Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-671
Web of Science | Medline
- Citing Articles (172)
Citing Articles
1
Marina Svetel, Tatjana Smiljković, Tatjana Pekmezović, Vladimir Kostić. (2012) Hallucinations in Parkinson’s disease: cross-sectional study. Acta Neurologica Belgica
CrossRef2
Richard B. Berry. 2012. Sleep and Neurologic Disorders. , 631-645.
CrossRef3
David A. Gallagher, Anette Schrag. (2012) Psychosis, Apathy, Depression and Anxiety in Parkinson's Disease. Neurobiology of Disease
CrossRef4
Philippe Huot, Susan H. Fox, Jonathan M. Brotchie. (2011) The serotonergic system in Parkinson's disease. Progress in Neurobiology 95:2, 163-212
CrossRef5
Stewart A. Factor, N. Kyle Steenland, Donald S. Higgins, Eric S. Molho, Denise M. Kay, Jennifer Montimurro, Ami R. Rosen, Cyrus P. Zabetian, Haydeh Payami. (2011) Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease. Movement Disorders 26:12, 2190-2195
CrossRef6
Mark Stacy. (2011) Nonmotor Symptoms in Parkinson's Disease. International Journal of Neuroscience 121:S2, 9-17
CrossRef7
Yoland Smith, Thomas Wichmann, Stewart A Factor, Mahlon R DeLong. (2011) Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa. Neuropsychopharmacology
CrossRef8
Y. Auxéméry. (2011) Dyskinésies tardives secondaires aux neuroleptiques et antipsychotiques : quelles perspectives thérapeutiques ?. Annales Médico-psychologiques, revue psychiatrique 169:8, 528-535
CrossRef9
Jennifer G Goldman, Christina L Vaughan, Christopher G Goetz. (2011) An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opinion on Pharmacotherapy 12:13, 2009-2024
CrossRef10
Chie Usui, Kotaro Hatta, Nagafumi Doi, Shinichiro Kubo, Rie Kamigaichi, Atsushi Nakanishi, Hiroyuki Nakamura, Nobutaka Hattori, Heii Arai. (2011) Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35:7, 1704-1708
CrossRef11
Meng-Ting Wang, Pei-Wen Lian, Chin-Bin Yeh, Che-Hung Yen, Kao-Hsing Ma, Agnes L.F. Chan. (2011) Incidence, prescription patterns, and determinants of antipsychotic use in patients with Parkinson's disease. Movement Disorders 26:9, 1663-1669
CrossRef12
Murat Emre. 2011. Treatment of Dementia Associated with Parkinson's Disease. , 163-169.
CrossRef13
Friederike Sixel-Döring, Claudia Trenkwalder. 2011. Sleep Disorders in Parkinson's Disease. , 233-239.
CrossRef14
Joseph H. Friedman. 2011. Psychosis in Parkinson's Disease. , 170-182.
CrossRef15
Santiago Perez-Lloret, María Verónica Rey, Luca Ratti, Olivier Rascol. (2011) Pramipexole for the treatment of early Parkinson’s disease. Expert Review of Neurotherapeutics 11:7, 925-935
CrossRef16
Avrom L. Kurtz, Daniel I. Kaufer. (2011) Dementia in Parkinson’s Disease. Current Treatment Options in Neurology 13:3, 242-254
CrossRef17
Alana Iglewicz, Thomas W. Meeks, Dilip V. Jeste. (2011) New Wine in Old Bottle: Late-life Psychosis. Psychiatric Clinics of North America 34:2, 295-318
CrossRef18
Daniel Weintraub, David J. Burn. (2011) Parkinson's disease: The quintessential neuropsychiatric disorder. Movement Disorders 26:6, 1022-1031
CrossRef19
Michael J. Aminoff, Chad W. Christine, Joseph H. Friedman, Kelvin L. Chou, Kelly E. Lyons, Rajesh Pahwa, Bastian R. Bloem, Sotirios A. Parashos, Catherine C. Price, Irene A. Malaty, Robert Iansek, Ivan Bodis-Wollner, Oksana Suchowersky, Wolfgang H. Oertel, Jorge Zamudio, Joyce Oberdorf, Peter Schmidt, Michael S. Okun. (2011) Management of the hospitalized patient with Parkinson’s disease: Current state of the field and need for guidelines. Parkinsonism & Related Disorders 17:3, 139-145
CrossRef20
Dag Aarsland, Uwe Ehrt, Irena Rektorova. (2011) Cognitive and psychiatric disturbances in Parkinson’s disease. Aging Health 7:1, 123-142
CrossRef21
Lothar Burghaus, Carsten Eggers, Lars Timmermann, Gereon R. Fink, Nico J. Diederich. (2011) Hallucinations in Neurodegenerative Diseases. CNS Neuroscience & Therapeuticsno-no
CrossRef22
Claudio L. Bassetti. (2011) Nonmotor Disturbances in Parkinson’s Disease. Neurodegenerative Diseases 8:3, 95-108
CrossRef23
Stanley Fahn, Joseph Jankovic, Mark Hallett. 2011. Medical treatment of Parkinson disease. , 119-156.
CrossRef24
Jennifer G. Goldman. (2011) New Thoughts on Thought Disorders in Parkinson's Disease: Review of Current Research Strategies and Challenges. Parkinson's Disease 2011, 1-12
CrossRef25
Stanley Fahn, Joseph Jankovic, Mark Hallett. 2011. The tardive syndromes. , 415-446.
CrossRef26
Stanley Fahn, Joseph Jankovic, Mark Hallett. 2011. Nonmotor problems in Parkinson disease. , 183-196.
CrossRef27
Joseph H. Friedman. (2010) Parkinson’s disease psychosis 2010: A review article. Parkinsonism & Related Disorders 16:9, 553-560
CrossRef28
Santiago Perez-Lloret, Olivier Rascol. (2010) Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinsonʼs Disease. CNS Drugs 24:11, 941-968
CrossRef29
W. H. Oertel, A. Berardelli, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, J. J. Ferreira, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder. 2010. Early (Uncomplicated) Parkinson's Disease. , 217-236.
CrossRef30
W. H. Oertel, A. Berardelli, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, J. J. Ferreira, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder. 2010. Late (Complicated) Parkinson's Disease. , 237-267.
CrossRef31
Manoj Mittal, Louis T. Giron. (2010) Elvis Is Back: Musical Hallucinations in a Parkinson Disease Patient. Southern Medical Journal 103:8, 837-841
CrossRef32
Philippe Huot, Tom H. Johnston, Tayyeba Darr, Lili-Naz Hazrati, Naomi P. Visanji, Donna Pires, Jonathan M. Brotchie, Susan H. Fox. (2010) Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Movement Disorders 25:10, 1399-1408
CrossRef33
Laura B. Zahodne, Hubert H. Fernandez. (2010) Parkinson’s Psychosis. Current Treatment Options in Neurology 12:3, 200-211
CrossRef34
David J. Burn. (2010) The Treatment of Cognitive Impairment Associated with Parkinson's Disease. Brain Pathology 20:3, 672-678
CrossRef35
Joseph H. Friedman. (2010) Recommendations on the Drug Treatment of Psychosis in Parkinson's Disease. The American Journal of Medicine 123:4, e19
CrossRef36
Herbert Y Meltzer, Roger Mills, Stephen Revell, Hilde Williams, Ann Johnson, Daun Bahr, Joseph H Friedman. (2010) Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis. Neuropsychopharmacology 35:4, 881-892
CrossRef37
Alessandro Stefani, Mariangela Pierantozzi, Giacomo Koch, Salvatore Galati, Paolo Stanzione. (2010) Therapy for dyskinesias in Parkinson’s disease patients. Future Neurology 5:2, 277-299
CrossRef38
Stanley Fahn. (2010) Parkinson's disease: 10 years of progress, 1997-2007. Movement Disorders 25:S1, S2-S14
CrossRef39
Christopher G. Goetz. (2010) New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease. Movement Disorders 25:S1, S104-S109
CrossRef40
Alissa A. Thomas, Joseph H. Friedman. (2010) Current Use of Clozapine in Parkinson Disease and Related Disorders. Clinical Neuropharmacology 33:1, 14-16
CrossRef41
Shen-Yang Lim, Anthony E. Lang. (2010) The nonmotor symptoms of Parkinson's disease-An overview. Movement Disorders 25:S1, S123-S130
CrossRef42
L.B. Zahodne, H.H. Fernandez. 2010. Psychosis in Parkinsonism. , 499-505.
CrossRef43
William J. Weiner. (2009) What do clinical trials tell us about treating patients?. Parkinsonism & Related Disorders 15, S34-S37
CrossRef44
HUBERT H. FERNANDEZ, MICHAEL S. OKUN, RAMON L. RODRIGUEZ, IRENE A. MALATY, JANET ROMRELL, ANQI SUN, SAMUEL S. WU, SANDEEP PILLARISETTY, ANAND NYATHAPPA, STEPHAN EISENSCHENK. (2009) QUETIAPINE IMPROVES VISUAL HALLUCINATIONS IN PARKINSON DISEASE BUT NOT THROUGH NORMALIZATION OF SLEEP ARCHITECTURE: RESULTS FROM A DOUBLE-BLIND CLINICAL-POLYSOMNOGRAPHY STUDY. International Journal of Neuroscience 119:12, 2196-2205
CrossRef45
Nancy L Diaz, Cheryl H Waters. (2009) Current strategies in the treatment of Parkinson’s disease and a personalized approach to management. Expert Review of Neurotherapeutics 9:12, 1781-1789
CrossRef46
Josè Martin Rabey. (2009) Hallucinations and psychosis in Parkinson's disease. Parkinsonism & Related Disorders 15, S105-S110
CrossRef47
Heinz Reichmann, Christine Schneider, Matthias Löhle. (2009) Non-motor features of Parkinson's disease: depression and dementia. Parkinsonism & Related Disorders 15, S87-S92
CrossRef48
Dag Aarsland, Laura Marsh, Anette Schrag. (2009) Neuropsychiatric symptoms in Parkinson's disease. Movement Disorders 24:15, 2175-2186
CrossRef49
Matthias Löhle, Alexander Storch, Heinz Reichmann. (2009) Beyond tremor and rigidity: non-motor features of Parkinson’s disease. Journal of Neural Transmission 116:11, 1483-1492
CrossRef50
Mark Stacy. (2009) Medical Treatment of Parkinson Disease. Neurologic Clinics 27:3, 605-631
CrossRef51
Mehrul Hasnain, W. Victor R. Vieweg, Mark S. Baron, Mary Beatty-Brooks, Antony Fernandez, Anand K. Pandurangi. (2009) Pharmacological Management of Psychosis in Elderly Patients with Parkinsonism. The American Journal of Medicine 122:7, 614-622
CrossRef52
Nico J. Diederich, Gilles Fénelon, Glenn Stebbins, Christopher G. Goetz. (2009) Hallucinations in Parkinson disease. Nature Reviews Neurology 5:6, 331-342
CrossRef53
Myra G. Schneider, Christopher J. Swearingen, Lisa M. Shulman, Jian Ye, Mona Baumgarten, Barbara C. Tilley. (2009) Minority enrollment in Parkinson's disease clinical trials. Parkinsonism & Related Disorders 15:4, 258-262
CrossRef54
Victoria Chang, Joseph H Friedman. (2009) Motor side effects of atypical antipsychotic drugs. Therapy 6:2, 249-258
CrossRef55
(2009) Correspondence. Australian and New Zealand Journal of Psychiatry 43:7, 689-693
CrossRef56
Tiffini S. Voss, Alicia F.D. Brocht, Bernard Ravina. (2009) Performance of the scale for assessment of positive symptoms in Parkinson's disease psychosis. Movement DisordersNA-NA
CrossRef57
David B Sommer, Mark A Stacy. (2008) What’s in the pipeline for the treatment of Parkinson’s disease?. Expert Review of Neurotherapeutics 8:12, 1829-1839
CrossRef58
Christopher G. Goetz, Wenqing Fan, Sue Leurgans. (2008) Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. Movement Disorders 23:11, 1541-1545
CrossRef59
Kelvin L. Chou. (2008) Adverse Events from the Treatment of Parkinson's Disease. Neurologic Clinics 26:3, 65-83
CrossRef60
M.-A. Crocq, V. Camus, B. Millet, J. Glickman, J.-M. Azorin, M.-O. Krebs, F. Limosin, J. Costentin, J. Daléry. (2008) Potentialités cliniques et perspectives d’utilisation de l’aripiprazole hors de ses champs classiques d’indication. L'Encéphale 34:2, 187-193
CrossRef61
Hubert H. Fernandez, Dag Aarsland, Gilles Fénelon, Joseph H. Friedman, Laura Marsh, Alexander I. Tröster, Werner Poewe, Olivier Rascol, Cristina Sampaio, Glenn T. Stebbins, Christopher G. Goetz. (2008) Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Movement Disorders 23:4, 484-500
CrossRef62
Miguel Coelho, Joaquim Ferreira, Mário Rosa, Cristina Sampaio. (2008) Treatment options for non-motor symptoms in late-stage Parkinson's disease. Expert Opinion on Pharmacotherapy 9:4, 523-535
CrossRef63
Ubaldo Bonuccelli, Roberto Ceravolo. (2008) The safety of dopamine agonists in the treatment of Parkinson's disease. Expert Opinion on Drug Safety 7:2, 111-127
CrossRef64
Daniel D. Truong, Roongroj Bhidayasiri, Erik Wolters. (2008) Management of non-motor symptoms in advanced Parkinson disease. Journal of the Neurological Sciences 266:1-2, 216-228
CrossRef65
Anna-Lena Nordstrom, Mattias Mansson, Hristina Jovanovic, Per Karlsson, Christer Halldin, Lars Farde, Kimberly E. Vanover, Uli Hacksell, Mark R. Brann, Robert E. Davis, David M. Weiner. (2008) PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain. The International Journal of Neuropsychopharmacology 11:02,
CrossRef66
Harpreet S. Duggal, Ira Singh. (2008) Ziprasidone for drug-induced psychotic symptoms in Parkinson's Disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32:2, 583-584
CrossRef67
Rachel Goldmann Gross, Andrew Siderowf, Howard I. Hurtig. (2008) Cognitive Impairment in Parkinson’s Disease and Dementia with Lewy Bodies: A Spectrum of Disease. Neurosignals 16:1, 24-34
CrossRef68
Laura B Zahodne, Hubert H Fernandez. (2008) Pathophysiology and Treatment of Psychosis in Parkinson’s Disease. Drugs & Aging 25:8, 665-682
CrossRef69
Carsten Buhmann. (2007) Morbus Parkinson: Klinik, Differenzialdiagnostik und Therapie. Von Priv.-Doz. Dr. med. Carsten Buhmann, Universitätsklinikum Eppendorf, Hamburg. focus neurogeriatrie 1:4, 33-39
CrossRef70
Marco Onofrj, Astrid Thomas, Laura Bonanni. (2007) New approaches to understanding hallucinations in Parkinson’s disease: phenomenology and possible origins. Expert Review of Neurotherapeutics 7:12, 1731-1750
CrossRef71
Miguel Coelho, Joaquim Ferreira, Cristina Sampaio. 2007. Parkinson's Disease. , 199-220.
CrossRef72
Maria J. Martí, Eduardo Tolosa, Andres Cerda. (2007) Dementia in Parkinson's disease. Journal of Neurology 254:S5, 41-48
CrossRef73
Bernard Ravina, Karen Marder, Hubert H. Fernandez, Joseph H. Friedman, William McDonald, Diane Murphy, Dag Aarsland, Debra Babcock, Jefferey Cummings, Jean Endicott, Stewart Factor, Wendy Galpern, Andrew Lees, Laura Marsh, Mark Stacy, Katrina Gwinn-Hardy, Valerie Voon, Christopher Goetz. (2007) Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group. Movement Disorders 22:8, 1061-1068
CrossRef74
Daniel Weintraub, Matthew B Stern. (2007) Intervening in the neuropsychiatric features of Parkinson’s disease. Expert Review of Neurotherapeutics 7:6, 699-710
CrossRef75
Anne PF Wand. (2007) Distinguishing dementia with Lewy bodies from dementia occurring in Parkinson's disease: A literature review. Australasian Journal on Ageing 26:2, 58-63
CrossRef76
Leora L Borek, Kelvin L Chou, Joseph H Friedman. (2007) Management of the behavioral aspects of Parkinson’s disease. Expert Review of Neurotherapeutics 7:6, 711-725
CrossRef77
Kelvin L Chou, Leora L Borek, Joseph H Friedman. (2007) The management of psychosis in movement disorder patients. Expert Opinion on Pharmacotherapy 8:7, 935-943
CrossRef78
Kelvin L Chou, Joseph H Friedman. (2007) Drug-induced parkinsonism in the elderly. Future Neurology 2:3, 307-316
CrossRef79
Thomas Müller. (2007) Rivastigmine in the treatment of patients with Alzheimer's disease. Neuropsychiatric Disease and Treatment 3:2, 211-218
CrossRef80
Rita Moretti, Paola Torre, Cristina Vilotti, Rodolfo M. Antonello, Gilberto Pizzolato. (2007) Rivastigmine and Parkinson dementia complex. Expert Opinion on Pharmacotherapy 8:6, 817-829
CrossRef81
Jose M. Rabey, Tatiana Prokhorov, Ala Miniovitz, Eugenia Dobronevsky, Colin Klein. (2007) Effect of quetiapine in psychotic Parkinson's disease patients: A double-blind labeled study of 3 months' duration. Movement Disorders 22:3, 313-318
CrossRef82
Joseph Jankovic, Mark Stacy. (2007) Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson???s Disease. CNS Drugs 21:8, 677-692
CrossRef83
Subramoniam Madhusoodanan, Payal Shah, Ronald Brenner, Sanjay Gupta. (2007) Pharmacological Treatment of the Psychosis of Alzheimer???s Disease. CNS Drugs 21:2, 101-115
CrossRef84
M. Emre. (2007) Treatment of dementia associated with Parkinson's disease. Parkinsonism & Related Disorders 13, S457-S461
CrossRef85
Nuria Caballol, Maria J Martí, Eduardo Tolosa. (2007) Cognitive dysfunction and dementia in Parkinson disease. Movement Disorders 22:S17, S358-S366
CrossRef86
Sharon Muzerengi, Helen Lewis, Mark Edwards, Emma Kipps, Anuj Bahl, Pablo Martinez-Martin, K Ray Chaudhuri. (2006) Non-motor symptoms in Parkinson's disease: an underdiagnosed problem. Aging Health 2:6, 967-982
CrossRef87
Joseph H. Friedman, Robert M. Berman, Christopher G. Goetz, Stewart A. Factor, William G. Ondo, Joanne Wojcieszek, William H. Carson, Ronald N. Marcus. (2006) Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Movement Disorders 21:12, 2078-2081
CrossRef88
I-Shin Shiah, Chun-Lung Lin, Wei-Chung Mao, Sy-Ueng Luu. (2006) Ziprasidone in the treatment of Parkinson’s disease psychosis. European Psychiatry 21:8, 578-579
CrossRef89
M. Horstink, E. Tolosa, U. Bonuccelli, G. Deuschl, A. Friedman, P. Kanovsky, J. P. Larsen, A. Lees, W. Oertel, W. Poewe, O. Rascol, C. Sampaio. (2006) Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society?European Section. Part I: early (uncomplicated) Parkinson's disease. European Journal of Neurology 13:11, 1170-1185
CrossRef90
M. Horstink, E. Tolosa, U. Bonuccelli, G. Deuschl, A. Friedman, P. Kanovsky, J. P. Larsen, A. Lees, W. Oertel, W. Poewe, O. Rascol, C. Sampaio. (2006) Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. European Journal of Neurology 13:11, 1186-1202
CrossRef91
Naomi P. Visanji, Jordi Gomez-Ramirez, Tom H. Johnston, Donna Pires, Valerie Voon, Jonathan M. Brotchie, Susan H. Fox. (2006) Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Movement Disorders 21:11, 1879-1891
CrossRef92
Maria A Mena, Justo G de Yébenes. (2006) Drug-induced parkinsonism. Expert Opinion on Drug Safety 5:6, 759-771
CrossRef93
Kelvin L Chou, Joseph H Friedman. (2006) Use of atypical antipsychotics in neurodegenerative diseases. Future Neurology 1:5, 553-562
CrossRef94
Brian C. Salter, Karen E. Anderson, William J. Weiner. (2006) Psychosis in Parkinson's Disease: Case Studies. Neurologic Clinics 24:2, 363-369
CrossRef95
Kelvin L Chou, Hubert H Fernandez. (2006) Combating psychosis in Parkinson’s disease patients: the use of antipsychotic drugs. Expert Opinion on Investigational Drugs 15:4, 339-349
CrossRef96
T. Prohorov, C. Klein, A. Miniovitz, E. Dobronevsky, J. M. Rabey. (2006) The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. Journal of Neurology 253:2, 171-175
CrossRef97
Matthew A Menza, Roseanne D Dobkin, Humberto Marin. (2006) Cognitive and psychiatric aspects of Parkinson’s disease: treatment recommendations. Aging Health 2:1, 87-99
CrossRef98
2006. Clozapine. , 823-841.
CrossRef99
Jeffrey L. Cummings, Kate Zhong. (2006) Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. Nature Reviews Drug Discovery 5:1, 64-74
CrossRef100
Arvid Rongve, Dag Aarsland. (2006) Management of Parkinson???s Disease Dementia. Drugs & Aging 23:10, 807-822
CrossRef101
Caroline H Williams-Gray, Thomas Foltynie, Simon J G Lewis, Roger A Barker. (2006) Cognitive Deficits and Psychosis in Parkinson???s Disease. CNS Drugs 20:6, 477-505
CrossRef102
D WEINTRAUB. (2005) Pharmacologic Interventions for Psychosis and Agitation in Neurodegenerative Diseases: Evidence About Efficacy and Safety. Psychiatric Clinics of North America 28:4, 941-983
CrossRef103
William G. Ondo, Ron Tintner, Kevin Dat Voung, Dejian Lai, George Ringholz. (2005) Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Movement Disorders 20:8, 958-963
CrossRef104
Albert FG Leentjens, Rose C van der Mast. (2005) Delirium in elderly people: an update. Current Opinion in Psychiatry 18:3, 325-330
CrossRef105
Matthias Oechsner, Alexei Korchounov. (2005) Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease?. Human Psychopharmacology: Clinical and Experimental 20:3, 203-205
CrossRef106
Hasmet A. Hanagasi, Murat Emre. (2005) Treatment of behavioural symptoms and dementia in Parkinson's disease. Fundamental and Clinical Pharmacology 19:2, 133-146
CrossRef107
Nico J. Diederich, Christopher G. Goetz, Glenn T. Stebbins. (2005) Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: Focused review and a new integrative model. Movement Disorders 20:2, 130-140
CrossRef108
Dilip V. Jeste, Christian R. Dolder, Gauri V. Nayak, Carl Salzman. (2005) Atypical Antipsychotics in Elderly Patients with Dementia or Schizophrenia: Review of Recent Literature. Harvard Review of Psychiatry 13:6, 340-351
CrossRef109
Hubert H. Fernandez, Martha E. Trieschmann, Michael S. Okun. (2005) Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease. Movement Disorders 20:1, 104-105
CrossRef110
Claudia Trenkwalder. 2005. Parkinsonism. , 801-810.
CrossRef111
Richard M. Trosch. (2004) Neuroleptic-Induced Movement Disorders: Deconstructing Extrapyramidal Symptoms. Journal of the American Geriatrics Society 52, S266-S271
CrossRef112
Ira R. Katz. (2004) Optimizing Atypical Antipsychotic Treatment Strategies in the Elderly. Journal of the American Geriatrics Society 52, S272-S277
CrossRef113
D. M. Weiner, H. Y. Meltzer, I. Veinbergs, E. M. Donohue, T. A. Spalding, T. T. Smith, N. Mohell, S. C. Harvey, J. Lameh, N. Nash, K. E. Vanover, R. Olsson, K. Jayathilake, M. Lee, A. I. Levey, U. Hacksell, E. S. Burstein, R. E. Davis, M. R. Brann. (2004) The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 177:1-2, 207-216
CrossRef114
E LAUTERBACH. (2004) The neuropsychiatry of Parkinson's disease and related disorders. Psychiatric Clinics of North America 27:4, 801-825
CrossRef115
Hubert H. Fernandez, Joseph H. Friedman, M. Cecilia Lansang, Stewart A. Factor, Eric S. Molho, D. Jim Coskun. (2004) Diabetes mellitus among parkinsonian patients treated chronically with clozapine. Parkinsonism & Related Disorders 10:7, 439-441
CrossRef116
Jack J. Chen. (2004) Anxiety, depression, and psychosis in Parkinson's disease: unmet needs and treatment challenges. Neurologic Clinics 22:3, S63-S90
CrossRef117
Steven J. Frucht. (2004) Parkinson Disease: An Update. The Neurologist 10:4, 185-194
CrossRef118
Hubert H. Fernandez, Edward M. Donnelly, Joseph H. Friedman. (2004) Long-term outcome of clozapine use for psychosis in parkinsonian patients. Movement Disorders 19:7, 831-833
CrossRef119
Daniele Fabio Zullino, Pierre-Yves Rodondi. (2004) Parkinson's disease masked by clozapine: a case report. General Hospital Psychiatry 26:4, 333-334
CrossRef120
Laura Marsh. (2004) Psychosis in Parkinson’s disease. Current Treatment Options in Neurology 6:3, 181-189
CrossRef121
Ali Samii, John G Nutt, Bruce R Ransom. (2004) Parkinson's disease. The Lancet 363:9423, 1783-1793
CrossRef122
JLW Bosboom, ECh Wolters. (2004) Psychotic symptoms in Parkinson’s disease: pathophysiology and management. Expert Opinion on Drug Safety 3:3, 209-220
CrossRef123
Ashwin A. Patkar, Rajnish Mago, Prakash S. Masand. (2004) Psychotic symptoms in patients with medical disorders. Current Psychiatry Reports 6:3, 216-224
CrossRef124
Gail A. Kang, Jeff M. Bronstein. (2004) Psychosis in Nursing Home Patients With Parkinson's Disease. Journal of the American Medical Directors Association 5:3, 167-173
CrossRef125
Jorge L. Juncos, Vicki J. Roberts, Marian L. Evatt, Rita D. Jewart, Colleen D. Wood, Larry S. Potter, Hann-Chang Jou, Paul P. Yeung. (2004) Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Movement Disorders 19:1, 29-35
CrossRef126
Letterio Morgante, Antonio Epifanio, Edoardo Spina, Mario Zappia, Antonio E Di Rosa, Roberto Marconi, Giorgio Basile, Giorgio Di Raimondo, Paolo La Spina, Aldo Quattrone. (2004) Quetiapine and Clozapine in Parkinsonian Patients With Dopaminergic Psychosis. Clinical Neuropharmacology 27:4, 153-156
CrossRef127
Gail A. Kang, Jeff M. Bronstein. (2004) Psychosis in Nursing Home Patients With Parkinson???s Disease. Journal of the American Medical Directors Association 5:3, 167
CrossRef128
Jan Herzog, Julia Reiff, Paul Krack, Karsten Witt, Bettina Schrader, Dieter M
ller, G
CrossRef129
Janet Romrell, Hubert H Fernandez, Michael S Okun. (2003) Rationale for current therapies in Parkinson’s disease. Expert Opinion on Pharmacotherapy 4:10, 1747-1761
CrossRef130
Werner Poewe. (2003) Psychosis in Parkinson's disease. Movement Disorders 18:S6, 80-87
CrossRef131
(2003) The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations. Movement Disorders 18:7, 738-750
CrossRef132
Hubert H. Fernandez, Martha E. Trieschmann, Monica A. Burke, Carol Jacques, Joseph H. Friedman. (2003) Long-term outcome of quetiapine use for psychosis among parkinsonian patients. Movement Disorders 18:5, 510-514
CrossRef133
Elie Paul Elovic, Ramon Lansang, Yali Li, Joseph H. Ricker. (2003) The Use of Atypical Antipsychotics in Traumatic Brain Injury. Journal of Head Trauma Rehabilitation 18:2, 177-195
CrossRef134
Laura Marsh, Ariel Berk. (2003) Neuropsychiatric aspects of Parkinson’s disease: Recent advances. Current Psychiatry Reports 5:1, 68-76
CrossRef135
Olivier Rascol, Pierre Payoux, Fabienne Ory, Joaquim J. Ferreira, Christine Brefel-Courbon, Jean-Louis Montastruc. (2003) Limitations of current Parkinson's disease therapy. Annals of Neurology 53:S3, S3-S15
CrossRef136
Joseph H. Friedman. 2003. Mental Changes in Parkinson's Disease. , 763-766.
CrossRef137
Hubert H Fernandez, Martha E Trieschmann, Joseph H Friedman. (2003) Treatment of Psychosis in Parkinson???s Disease. Drug Safety 26:9, 643-659
CrossRef138
Alan Breier, Virginia K Sutton, Peter D Feldman, Deborah L Kadam, Iris Ferchland, Padraig Wright, Joseph H Friedman. (2002) Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biological Psychiatry 52:5, 438-445
CrossRef139
William G. Ondo, Joel K. Levy, Kevin Dat Vuong, Christine Hunter, Joseph Jankovic. (2002) Olanzapine treatment for dopaminergic-induced hallucinations. Movement Disorders 17:5, 1031-1035
CrossRef140
K. Alptekin, B.B. Kvrck. (2002) Quetiapine-induced improvement of tardive dyskinesia in three patients with schizophrenia. International Clinical Psychopharmacology 17:5, 263-264
CrossRef141
Karen E. Anderson, William J. Weiner. (2002) Psychiatric symptoms in Parkinson’s disease. Current Neurology and Neuroscience Reports 2:4, 303-309
CrossRef142
Sujana Reddy, Stewart A. Factor, Eric S. Molho, Paul J. Feustel. (2002) The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Movement Disorders 17:4, 676-681
CrossRef143
Olivier Rascol, Christopher Goetz, William Koller, Werner Poewe, Cristina Sampaio. (2002) Treatment interventions for Parkinson's disease: an evidence based assessment. The Lancet 359:9317, 1589-1598
CrossRef144
Thomas Müller. (2002) Drug treatment of non-motor symptoms in Parkinson’s disease. Expert Opinion on Pharmacotherapy 3:4, 381-388
CrossRef145
Daniel Tarsy, Ross J. Baldessarini, Frank I. Tarazi. (2002) Effects of Newer Antipsychotics on Extrapyramidal Function. CNS Drugs 16:1, 23-45
CrossRef146
Peter F. Buckley. (2001) Broad therapeutic uses of atypical antipsychotic medications. Biological Psychiatry 50:11, 912-924
CrossRef147
L. Marsh. (2001) Olanzapine for the Treatment of Psychosis in Patients With Parkinson's Disease and Dementia. Psychosomatics 42:6, 477-481
CrossRef148
Paul J. Reading, Anna K Luce, Ian G. McKeith. (2001) Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial. Movement Disorders 16:6, 1171-1174
CrossRef149
Eric S. Molho, Stewart A. Factor. (2001) Parkinson’s disease: The treatment of drug-induced hallucinations and psychosis. Current Neurology and Neuroscience Reports 1:4, 320-328
CrossRef150
Erik Ch. Wolters, Henk W. Berendse. (2001) Management of psychosis in Parkinsonʼs disease. Current Opinion in Neurology 14:4, 499-504
CrossRef151
David B. Arciniegas, Jeannie L. Topkoff, Kerri Held, Lauren Frey. (2001) Psychosis due to neurologic conditions. Current Treatment Options in Neurology 3:4, 347-364
CrossRef152
Michael Bubser, Jon R. Backstrom, Elaine Sanders-Bush, Bryan L. Roth, Ariel Y. Deutch. (2001) Distribution of serotonin 5-HT2A receptors in afferents of the rat striatum. Synapse 39:4, 297-304
CrossRef153
Sandra Campbell, Sally Stephens, Clive Ballard. (2001) Dementia with Lewy Bodies. Drugs & Aging 18:6, 397-407
CrossRef154
Maria L. Bäckman, Laura E. berg, Eeva T. Aronen, Pirkko R. Santavuori. (2001) New antidepressive and antipsychotic drugs in juvenile neuronal ceroid lipofuscinoses — a pilot study. European Journal of Paediatric Neurology 5, 163-166
CrossRef155
Stewart A. Factor, Joseph H. Friedman, Margaret C. Lannon, David Oakes, Keith Bourgeois, . (2001) Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial. Movement Disorders 16:1, 135-139
CrossRef156
Matthew J. Byerly, Mary T. Weber, Deean L. Brooks, Lisa R. Snow, Mark A. Worley, Emmeline Lescouflair. (2001) Antipsychotic Medications and the Elderly. Drugs & Aging 18:1, 45-61
CrossRef157
Ian G. McKeith, David Burn. (2000) SPECTRUM OF PARKINSON'S DISEASE, PARKINSON'S DEMENTIA, AND LEWY BODY DEMENTIA. Neurologic Clinics 18:4, 865-883
CrossRef158
Marcos Serrano-Due
CrossRef159
A.A. Rabinstein, L.M. Shulman. (2000) Management of behavioral and psychiatric problems in Parkinson's disease. Parkinsonism & Related Disorders 7:1, 41-50
CrossRef160
Joseph H. Friedman, Stewart A. Factor. (2000) Reply. Movement Disorders 15:6, 1300-1300
CrossRef161
Joseph H. Friedman, Stewart A. Factor. (2000) Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Movement Disorders 15:2, 201-211
CrossRef162
Brian C Lund, Paul J Perry. (2000) Olanzapine: an atypical antipsychotic for schizophrenia. Expert Opinion on Pharmacotherapy 1:2, 305-323
CrossRef163
Laura Marsh. (2000) Neuropsychiatric Aspects of Parkinson’s Disease. Psychosomatics 41:1, 15-23
CrossRef164
I LAGOMASINO, R DALY, A STOUDEMIRE. (1999) MEDICAL ASSESSMENT OF PATIENTS PRESENTING WITH PSYCHIATRIC SYMPTOMS IN THE EMERGENCY SETTING. Psychiatric Clinics of North America 22:4, 819-850
CrossRef165
Richard T. Scheife. (1999) Successful Orchestration of Antiparkinsonian Pharmacotherapy. Pharmacotherapy 19:11 Part 2, 180S-186S
CrossRef166
Eric S. Molho, Stewart A. Factor. (1999) Worsening of motor features of Parkinsonism with olanzapine. Movement Disorders 14:6, 1014-1016
CrossRef167
Kate L. Lapane, Hubert H. Fernandez, Joseph H. Friedman, SAGE Study Group. (1999) Prevalence, Clinical Characteristics, and Pharmacologic Treatment of Parkinson’s Disease in Residents in Long-Term Care Facilities. Pharmacotherapy 19:11, 1321-1327
CrossRef168
(1999) Clozapine for Drug-Induced Psychosis in Parkinson's Disease. New England Journal of Medicine 341:6, 456-456
Full Text169
Dag Aarsland, Karen Karlsen. (1999) Neuropsychiatric aspects of parkinson’s disease. Current Psychiatry Reports 1:1, 61-68
CrossRef170
(1999) Clozapine in drug-induced psychosis in Parkinson's disease. The Lancet 353:9169, 2041-2042
CrossRef171
Cummings, Jeffrey L., . (1999) Managing Psychosis in Patients with Parkinson's Disease. New England Journal of Medicine 340:10, 801-803
Full Text172
&NA;. (1999) Clozapine improves antiparkinsonian drug-induced psychosis. Reactions Weekly &NA;:743, 4
CrossRef
- Letters
